3-(苄基氨基)哌啶-1-羧酸叔丁酯盐酸盐 | 183207-64-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(苄基氨基)哌啶-1-羧酸叔丁酯盐酸盐
• 中文别名: 1-Boc-3-(苄氨基)哌啶；1-BOC-3-(苄氨基)哌啶
• 英文名称: 3-benzylamino-1-boc-piperidine
• 英文别名: 3-benzylamino-1-(tert-butyloxycarbonyl)piperidine；N-Boc-3-aminopiperidine；Tert-butyl 3-(benzylamino)piperidine-1-carboxylate
• CAS: 183207-64-9
• 化学式: C₁₇H₂₆N₂O₂
• mdl: MFCD06410626
• 分子量: 290.406
• InChiKey: PYOZLJFLGIAVOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.588
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  N-BOC-3-羟基哌啶 、 苄胺 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 碘苯二乙酸 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以100%的产率得到3-(苄基氨基)哌啶-1-羧酸叔丁酯盐酸盐
  参考文献：
  名称：

  不含过渡金属的醇对胺的温和非配位化N-烷基化作用

  摘要：

  当涉及光学活性醇和胺时，涉及氧化/亚胺-亚胺形成/还原的一锅两步序列允许胺被醇的N-烷基化而没有任何差向异构化。

  DOI：

  10.1021/ol201351a

文献信息

• Tuning an Imine Reductase for the Asymmetric Synthesis of Azacycloalkylamines by Concise Structure‐Guided Engineering
  作者：Jun Zhang、Daohong Liao、Rongchang Chen、Fangfang Zhu、Yaqing Ma、Lei Gao、Ge Qu、Chengsen Cui、Zhoutong Sun、Xiaoguang Lei、Shu‐Shan Gao

  DOI：10.1002/anie.202201908

  日期：2022.6.13

  Structure-guided engineering of an imine reductase IR-G36 gave a final variant M5 for reductive amination, enabling the asymmetric synthesis of a series of azacycloalkylamines with up to 47 g L−1 substrate loadings and up to 99 % conversion and >99 % ee. Crystal structures of IR-G36 and computational studies shed light on the structural basis for the performance improvement.

  亚胺还原酶 IR-G36 的结构引导工程得到了用于还原胺化的最终变体 M5，从而能够不对称合成一系列氮杂环烷基胺，其底物负载量高达 47 g L -1，转化率高达 99 %，ee > 99 % . IR-G36 的晶体结构和计算研究揭示了性能改进的结构基础。
• 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3689871A1

  公开（公告）日：2020-08-05

  The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.

  本公开涉及4,6,7-三取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及其制剂和药用。具体地说，本公开公开了式(I)化合物或其药学上可接受的盐、立体异构体、溶媒或原药及其制备方法和用途，其中各组的定义如说明书和权利要求书中所述。
• 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US11155546B2

  公开（公告）日：2021-10-26

  The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.

  本公开涉及4,6,7-三取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及其制剂和药用。具体地说，本公开公开了式(I)化合物或其药学上可接受的盐、立体异构体、溶媒或原药及其制备方法和用途，其中各组的定义如说明书和权利要求书中所述。
• 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROLO[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVES AND USES THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20200223846A1

  公开（公告）日：2020-07-16

  The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.